#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Non-small cell lung cancer metastatic Asthma Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Precursor T-lymphoblastic lymphoma/leukaemia recurrent Hyperinsulinism B precursor type acute leukaemia Thalassaemia beta Systemic lupus erythematosus Alveolar rhabdomyosarcoma Primary hyperoxaluria Epilepsy Immunodeficiency common variable Osteogenesis imperfecta Myelodysplastic syndrome Carcinoid tumour Haemophilia B with anti factor IX Bulbospinal muscular atrophy congenital Fibrosarcoma metastatic More trials…

    Learn about Rare Diseases

    Sjogren’s syndrome – Trials in Disease Pemphigoid – Diagnostics Ehlers-Danlos syndrome – Basic Information Proteus syndrome – Basic Information Urea cycle disorder Erdheim-Chester disease – Trials in Disease Crigler-Najjar syndrome – Trials in Disease Friedreich’s ataxia – Treatment Urea cycle disorder – Diagnostics Haemolytic uraemic syndrome – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Golodirsen Lapatinib Landiolol Hydrochloride Atorvastatin Neomycin Sulfate Atezolizumab Lufepirsen Triamcinolone Acetonide Vinblastine Sulfate Eik1003 Dronabinol GLYCYL-TYROSINE Elinzanetant ALN-4324 Febuxostat GSKVX000000034794 Gen1053 Afm24 Azd8205 Aon-D21 More therapies…

    Learn about Your Condition

    Neuroblastoma recurrent Apathy Dermatomyositis Cystic fibrosis Interstitial lung disease Bile duct cancer Retinopathy of prematurity Cytomegalovirus infection Cervical dysplasia Neoplasm Endocarditis bacterial Uterine leiomyoma Muscular dystrophy Coronary artery dissection Arterial tortuosity syndrome More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Type 2 diabetes mellitus

  • Study of NNC0519-0130 and semaglutide in people with chronic kidney disease who are overweight or obese, with or without type 2 diabetes

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Type 2 diabetes mellitus
    • Chronic kidney disease
    • Obesity
    Investigated Drugs:
    • Semaglutide
    Bulgaria Italy Poland Spain

  • Study on the Safety and Effectiveness of Utreglutide (GL0034) for Adults with Type 2 Diabetes Not Well Managed with Metformin or Lifestyle Changes

    Not recruiting

    2 1
    Investigated Diseases:
    • Type 2 diabetes mellitus
    Investigated Drugs:
    • Utreglutide
    Germany

  • Study comparing semaglutide with insulin glargine in overweight adults with type 2 diabetes: effectiveness of combined treatment versus insulin alone

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Type 2 diabetes mellitus
    • Overweight
    Investigated Drugs:
    • Insulin Glargine
    • Semaglutide
    Czechia Greece Italy Portugal Romania Slovakia +1

  • Study on CK-0045 for Patients with Type 2 Diabetes and Obesity

    Not recruiting

    2 1
    Investigated Diseases:
    • Type 2 diabetes mellitus
    • Obesity
    Investigated Drugs:
    • Ck-0045
    Germany

  • Study on the Effects of Ertugliflozin and Sodium Intake on Blood Pressure in Overweight Adults with Type 2 Diabetes

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Type 2 diabetes mellitus
    Investigated Drugs:
    • Ertugliflozin
    The Netherlands

  • Study on the Safety and Effectiveness of Metformin Hydrochloride, Dapagliflozin, and Canagliflozin in Elderly Patients with Type 2 Diabetes

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Type 2 diabetes mellitus
    Investigated Drugs:
    • Canagliflozin
    • Empagliflozin
    • Metformin Hydrochloride
    Italy
Previous Page
1 … 7 8 9 10 11 … 13
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!